Live Analyst Rating Changes 3271 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Gary Nachman
CG
Gary Nachman
Wall Street Analyst
★★☆☆☆
#2295
on 13Foresight · ranked by our own returns
58%
Success Rate
+10.0%
Average Return
21 of 36 calls profitable · -132.5% vs benchmark
📈 Across the calls we could measure, roughly 58% of Gary Nachman's ratings turned a profit when each position was held for 1 year — averaging +10.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

36 Buy 6 Hold 0 Sell
Gary's Stock Coverage 36 ratings · 2026-06-27
Company Date Position Consensus Price Target 1-Yr Return
IONS
Ionis Pharmaceuticals
Jun 24, 2026 BUY Strong Buy
+4.1% avg upside
43 analysts
$110.00
35.43% Upside
+3.1%
ABBV
AbbVie
Jun 23, 2026 BUY Buy
-10.7% avg upside
44 analysts
$273.00
7.81% Upside
+3.6%
ACHV
Achieve Life Sciences
Jun 23, 2026 BUY Strong Buy
+156.7% avg upside
12 analysts
$13.00
115.88% Upside
·
ADMA
ADMA Biologics
Jun 14, 2026 BUY Strong Buy
+49.4% avg upside
15 analysts
$18.00
105.65% Upside
-2.2%
SRRK
Scholar Rock Holding
Jun 02, 2026 BUY Strong Buy
+4.2% avg upside
23 analysts
$62.00
13.22% Upside
+14.8%
AMGN
Amgen
May 01, 2026 HOLD Buy
-16.6% avg upside
57 analysts
$366.00
2.08% Upside
+9.5%
PCRX
Pacira Pharmaceuticals
Oct 06, 2025 HOLD Buy
+54.5% avg upside
21 analysts
+2.1%
TSE:EPRX
Eupraxia Pharmaceuticals
Oct 02, 2025 BUY Strong Buy
+143.3% avg upside
9 analysts
$17.08
82.08% Upside
·
VERU
Veru
Aug 13, 2025 BUY Strong Buy
+559.9% avg upside
10 analysts
$20.00
564.51% Upside
-30.5%
INMB
Inmune Bio
Aug 04, 2025 HOLD Buy
+769.7% avg upside
11 analysts
-56.6%
LENZ
LENZ Therapeutics
Jul 31, 2025 BUY Buy
+308.6% avg upside
17 analysts
$40.00
587.24% Upside
-77.1%
ANIP
ANI Pharmaceuticals
Jun 20, 2025 BUY Strong Buy
+21.2% avg upside
11 analysts
$86.00
1.86% Upside
+18.9%
AQST
Aquestive Therapeutics
Jun 17, 2025 BUY Strong Buy
+102.8% avg upside
10 analysts
$7.00
59.51% Upside
+32.2%
JAZZ
Jazz Pharmaceuticals
Jun 11, 2025 HOLD Strong Buy
-4.0% avg upside
35 analysts
+113.7%
BLCO
Bausch + Lomb Corporation
Feb 20, 2025 BUY Buy
+19.2% avg upside
19 analysts
$22.00
34.80% Upside
+12.9%
ALNY
Alnylam Pharma
Jan 15, 2025 BUY Strong Buy
+17.6% avg upside
51 analysts
$298.00
2.28% Upside
+43.1%
SLGL
Sol-Gel Technologies
Aug 19, 2024 BUY Strong Buy
+60.2% avg upside
6 analysts
$4.00
94.52% Downside
+277.5%
EVLO
Evelo Biosciences
Mar 16, 2023 BUY Buy
+4499999900.0% avg upside
5 analysts
$100.00
9999999899.98% Upside
·
AMRX
Amneal Pharmaceuticals
Mar 02, 2023 HOLD Strong Buy
-0.2% avg upside
18 analysts
$4.00
76.84% Downside
+174.9%
SDGR
Schrodinger
Mar 01, 2023 BUY Strong Buy
+68.2% avg upside
14 analysts
$78.00
362.62% Upside
+9.0%
PHAT
Phathom Pharmaceuticals
Mar 01, 2023 BUY Strong Buy
+171.4% avg upside
14 analysts
$30.00
179.89% Upside
+18.6%
VTRS
Viatris
Feb 27, 2023 HOLD Buy
+39.8% avg upside
21 analysts
$14.00
14.33% Downside
+23.9%
TSE:BHC
Bausch Health Companies
Feb 24, 2023 HOLD Buy
+784.5% avg upside
29 analysts
$14.24
110.27% Upside
·
ABCL
AbCellera Biologics
Feb 22, 2023 BUY Strong Buy
+78.6% avg upside
15 analysts
$32.00
333.63% Upside
-44.8%
TEVA
Teva Pharmaceutical
Feb 08, 2023 HOLD Buy
-11.6% avg upside
39 analysts
$10.00
69.89% Downside
+21.9%
RIGL
Rigel
Jan 09, 2023 BUY Strong Buy
-38.0% avg upside
17 analysts
$3.00
92.32% Downside
-2.8%
NMTRQ
9 Meters Biopharma
Nov 10, 2022 BUY Buy
+3234374900.0% avg upside
11 analysts
$35.00
3499999900.06% Upside
·
PYPD
PolyPid
Aug 11, 2022 BUY Strong Buy
+248.5% avg upside
7 analysts
$25.00
426.28% Upside
-94.2%
XCUR
Exicure
Aug 02, 2021 BUY Buy
+3828.6% avg upside
4 analysts
$180.00
7399.98% Upside
-97.1%
TRVI
Trevi Therapeutics
May 14, 2021 BUY Strong Buy
+11.5% avg upside
16 analysts
$12.00
33.93% Downside
+7.3%
AMPH
Amphastar Pharmaceuticals
May 11, 2020 HOLD Hold
+23.0% avg upside
11 analysts
$21.00
3.55% Downside
-1.0%
SNNAQ
Sienna Biopharmaceuticals
Sep 05, 2019 BUY Buy
+299999899.9% avg upside
2 analysts
$3.00
299999899.91% Upside
-66.7%
SGPYY
Sage Group
Sep 14, 2017 BUY Buy
+84.7% avg upside
4 analysts
$80.00
84.73% Upside
-19.7%
ZBH
Zimmer Biomet Holdings
Apr 27, 2017 BUY Buy
+20.9% avg upside
37 analysts
$138.00
48.14% Upside
-0.2%
IRWD
Ironwood Pharma
Mar 21, 2016 HOLD Buy
+188.8% avg upside
23 analysts
$14.00
238.98% Upside
+67.7%
AMRN
Amarin
Oct 09, 2013 HOLD Hold
-47.1% avg upside
18 analysts
$6.80
57.24% Downside
·
🔒 31 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Gary Nachman — Frequently Asked Questions
How accurate are Gary Nachman's stock ratings?
Based on the calls 13Foresight could measure, about 58% of Gary's ratings were profitable over a one-year hold, with an average return of +10.0% per rating, or -132.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Gary ranked on 13Foresight?
Gary Nachman is currently ranked #2295 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Gary cover?
Gary most recently has ratings on IONS, ABBV, ACHV, ADMA, SRRK, AMGN, PCRX, TSE:EPRX, VERU, INMB, LENZ, ANIP and 24 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.